EGFR and neoplasm: About 10%‐15% of advanced NSCLC patients are unable to receive treatment because tumor tissue samples are unavailable.17 Studies have shown a high degree of concordance of cfDNA analysis with tissue testing.18 In the IFUM study, the mutation status of EGFR in blood and matched tissues of 652 patients with NSCLC cancer was detected by ARMS.